Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 8/20 | 0.61 |
| ▸ | CDK7 | P50613 | 7/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.49 |
| ▸ | TYK2 | P29597 | 3/20 | 0.48 |
| ▸ | JAK3 | P52333 | 3/20 | 0.48 |
| ▸ | JAK1 | P23458 | 2/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 4/20 | 0.47 |
| ▸ | CLK2 | P49760 | 3/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.47 |
| ▸ | PLK4 | O00444 | 2/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.47 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | MARK3 | P27448 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24137560 | 0.84 | CDK2 (0.57) | JAK2CDK7JAK3CDK2DYRK1A | |
| SCHEMBL21318857 | 0.83 | JAK2 (0.56) | JAK2TYK2JAK3JAK1CDK2 | |
| SCHEMBL24137915 | 0.81 | JAK2 (0.57) | JAK2CDK7TYK2JAK3JAK1 | |
| SCHEMBL24137493 | 0.81 | JAK2 (0.53) | JAK2CDK7TYK2JAK3CDK2 | |
| SCHEMBL25938176 | 0.79 | CDK7 (0.45) | JAK2CDK7TYK2JAK3CDK2 | |
| SCHEMBL15799346 | 0.79 | CCNC (0.68) | JAK2CDK7CDK2ROCK1ROCK2 | |
| SCHEMBL15799347 | 0.79 | CCNC (0.68) | JAK2CDK7CDK2ROCK1ROCK2 | |
| SCHEMBL24137846 | 0.77 | CDK7 (0.52) | JAK2CDK7TYK2JAK3CDK2 | |
| SCHEMBL24137727 | 0.77 | JAK2 (0.52) | JAK2CDK7TYK2JAK3JAK1 | |
| SCHEMBL25936076 | 0.77 | JAK2 (0.48) | JAK2CDK7TYK2JAK3JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-07-27 | — | — | US | disclosed |
| WO-2021263129-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | PACSIN2, MAP3K20, PHKG1 | JAK2 228/4885CDK7 210/4885XDH 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.